XML 54 R37.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Assets and Liabilities Measured at Fair Value (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2016
Summary of assets and liabilities subject to fair value measurements | A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2016 are identified in the following table (in thousands):
|  | Level 2 |  | Total |
Commercial paper |  | $ | 68,390 |  | $ | 68,390 |
Corporate debt securities |  |  | 74,535 |  |  | 74,535 |
Money market funds |  |  | 1,829 |  |  | 1,829 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
|  | $ | 144,754 |  | $ | 144,754 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
|  | Level 2 |  | Level 3 |  | Total |
Liabilities: |  |  |  |  |  |  |  |  |  |
Contingent consideration payable |  | $ | — |  | $ | 269,722 |  | $ | 269,722 |
Derivative liability |  |  | 265 |  |  | — |  |  | 265 |
Deferred compensation plan liability |  |  | 1,479 |  |  | — |  |  | 1,479 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
|  | $ | 1,744 |  | $ | 269,722 |  | $ | 271,466 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
A summary of the fair value of the Company's assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2015 are identified in the following table (in thousands):
|  | Level 2 |  | Total |
Commercial paper |  |  | 25,724 |  |  | 25,724 |
Corporate debt securities |  |  | 118,474 |  |  | 118,474 |
Certificate of deposit |  |  | 350 |  |  | 350 |
Market exchanged mutual funds |  |  | 658 |  |  | 658 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
|  | $ | 145,206 |  | $ | 145,206 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
|  | Level 2 |  | Level 3 |  | Total |
Liabilities: |  |  |  |  |  |  |  |  |  |
Contingent consideration payable |  | $ | — |  | $ | 274,077 |  | $ | 274,077 |
Deferred compensation plan liability |  |  | 667 |  |  | — |  |  | 667 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
|  | $ | 667 |  | $ | 274,077 |  | $ | 274,744 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Schedule of changes in contingent consideration payable | The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2016 and 2015, respectively (in thousands):
|  | Year ended December 31, |
|  | 2016 |  | 2015 |
Balance, beginning of the period |  | $ | 274,077 |  | $ | 10,700 |
Additions, from business acquisitions |  |  | — |  |  | 259,000 |
Payment of contingent consideration in cash |  |  | (5,000 | ) |  | — |
Payment of contingent consideration in stock |  |  | (6,115 | ) |  | — |
Unrealized change in fair value change during the period, included in Statement of Operations |  |  | 6,760 |  |  | 4,377 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance, end of the period |  | $ | 269,722 |  | $ | 274,077 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Scioderm |
Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable |
Contingent Consideration Liability |  | Fair value as of December 31, 2016 |  | Valuation Technique |  | Unobservable Input |  | Range
|  |  |  |  |  | Discount rate |  | 0.62% - 3.8%
Clinical and regulatory milestones |  | $237.2 million |  | Probability weighted discounted cash flow |  | Probability of achievement of milestones |  | 66.5% - 100.0%
|  |  |  |  |  | Projected year of payments |  | 2017-2019
|  |  |  |  |  | Revenue volatility |  | 58%
|  |  |  |  |  | Probability of achievement of milestones |  | 66.5%
Revenue-based milestones |  | $22.8 million |  | Monte Carlo |  | Discount rate |  | 1.47% - 2.55%
|  |  |  |  |  | Projected year of payments |  | 2019-2029
Callidus |
Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable |
Contingent Consideration Liability |  | Fair value as of December 31, 2016 |  | Valuation Technique |  | Unobservable Input |  | Range
|  |  |  |  |  | Discount rate |  | 12.5%
Clinical and regulatory milestones |  | $9.3 million |  | Probability weighted discounted cash flow |  | Probability of achievement of milestones |  | 30.4%-42.8%
|  |  |  |  |  | Projected year of payments |  | 2018-2022

X
- Definition Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a,b,bb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2C -URI http://asc.fasb.org/extlink&oid=36462937&loc=SL7498348-110258 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments. + References No definition available. + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |